Solamargine triggers cellular necrosis selectively in different types of human melanoma cancer cells through extrinsic lysosomal mitochondrial death pathway by unknown
Al Sinani et al. Cancer Cell Int  (2016) 16:11 
DOI 10.1186/s12935-016-0287-4
PRIMARY RESEARCH
Solamargine triggers cellular necrosis 
selectively in different types of human 
melanoma cancer cells through extrinsic 
lysosomal mitochondrial death pathway
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Abstract 
Background: Previous reports showed that the Steroidal Glycoalkaloid Solamargine inhibited proliferation of non-
melanoma skin cancer cells. However, Solamargine was not tested systematically on different types of melanoma cells 
and was not simultaneously tested on normal cells either. In this study we aimed to investigate the effect of Solamar-
gine and the mechanism involved in inhibiting the growth of different types of melanoma cells.
Methods: Solamargine effect was tested on normal cells and on another three melanoma cell lines. Vertical growth 
phase metastatic and primary melanoma cell lines WM239 and WM115, respectively and the radial growth phase 
benign melanoma cells WM35 were used. The half inhibitory concentration IC50 of Solamargine was determined using 
Alamarblue assay. The cellular and subcellular changes were assessed using light and Transmission Electron Micro-
scope, respectively. The percentage of cells undergoing apoptosis and necrosis were measured using Flow cytometry. 
The different protein expression was detected and measured using western blotting. The efficacy of Solamargine 
was determined by performing the clonogenic assay. The data collected was analyzed statistically on the means of 
the triplicate of at least three independent repeated experiments using one-way ANOVA test for parametric data and 
Kruskal–Wallis for non-parametric data. Differences were considered significant when the P values were less than 0.05.
Results: Hereby, we demonstrate that Solamargine rapidly, selectively and effectively inhibited the growth of meta-
static and primary melanoma cells WM239 and WM115 respectively, with minimum effect on normal and benign 
WM35 cells. Solamargine caused cellular necrosis to the two malignant melanoma cell lines (WM115, WM239), by 
rapid induction of lysosomal membrane permeabilization as confirmed by cathepsin B upregulation which triggered 
the extrinsic mitochondrial death pathway represented by the release of cytochrome c and upregulation of TNFR1. 
Solamargine disrupted the intrinsic apoptosis pathway as revealed by the down regulation of hILP/XIAP, resulting in 
caspase-3 cleavage, upregulation of Bcl-xL, and Bcl2, and down regulation of Apaf-1 and Bax in WM115 and WM239 
cells only. Solamargine showed high efficacy in vitro particularly against the vertical growth phase melanoma cells.
Conclusion: Our findings suggest that Solamargine is a promising anti-malignant melanoma drug which warrants 
further attention.
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Background
Metastatic melanoma is the most lethal type of skin can-
cer, more prevalent within light skinned populations [1]. 
Although melanoma has lower incidence rate compared 
with other non-melanoma skin cancers (NMSC) it still 
counts for 50,000 annual deaths worldwide and it is more 
common in males compared to females in developed 
countries [2]. The latest USA cancer statistics report 
indicated that 43,890 cases were estimated to have mela-
noma skin cancer and the number of new cases showed 
an increase in 2014 [3]. Similarly, the incidence of mela-
noma within Australian susceptible youth is increasing as 
reported recently [4]. Metastatic melanoma is known for 
its resistance to chemotherapies notably those with anti-
apoptotic action [5–7].
Effective anti-cancer drugs need to selectively kill 
cancer cells with minimal effect on normal cells. Plant 
derived compounds such as paclitaxel, originally isolated 
from the plant Taxus brevifolia, are currently used, par-
ticularly for the treatment of melanoma and other types 
of cancer [8]. Increasing evidence shows that Solamar-
gine, a plant derived steroidal glycoalkaloid, also has 
anti-cancer activity [9, 10]. A previous study proved the 
efficacy of using a topical cream containing plant iso-
lated Solasodine rhamnosyl glycosides in the treatment 
of non-melanoma skin cancer [11]. Steroidal glycoalka-
loids (SGAs) are naturally occurring nitrogen containing 
secondary metabolites found in plants of the Solanaceae 
family. The two main compounds are Solasodine and 
Solamargine, and the main structural difference between 
them is the chacotriose sugar side chain which is found in 
Solamargine [12, 13].
Anti-cancer chemotherapies trigger extrinsic and intrin-
sic apoptotic signals in cancer cells [14]. Solamargine 
treatment up-regulated the expression of tumor necrosis 
factor receptors (TNF-R1 and TNF-R2) and the down-
stream signaling cascades of tumor necrosis factor recep-
tor type 1-Associated Death Domain protein (TRADD) 
and Fas-Associated Death Domain protein (FADD), along 
with the activation of the mitochondrial pathway of apop-
tosis, in human hepatocellular carcinoma, lung cancer 
cells, breast cancer cells (SK-BR3, MCF-7, HBL-100 and 
ZR-75-1) [9], human squamous cell carcinoma SCCs [15], 
and human leukemia (K562) cell lines [16].
However, to our knowledge the effect of Solamargine 
has not been thoroughly tested on human melanoma 
skin cancer cells. Therefore, we investigated the effect of 
Solamargine and the underlying mechanism of action on 
benign and malignant human melanoma cancer cell lines 
in vitro. We found that Solamargine selectively inhibited 
the highly proliferating malignant vertical growth phase 
(VGP) human melanoma cells lines WM115 and WM239 
with minimum effect on the benign radial growth phase 
(RGP) melanoma cell line WM35, or normal cells. Sola-
margine induced cellular death in these highly prolifera-
tive human melanoma cell lines primarily through the 
induction of necrosis and rapid rupture of cancer cells 
via activation of the lysosomal apoptotic pathway. Sola-
margine disrupted the intrinsic apoptosis pathway as 
revealed by the down regulation of hILP/XIAP, resulting 
in caspase-3 cleavage, upregulation of Bcl-xL, and Bcl2, 
and down regulation of Apaf-1 and Bax in WM115 and 
WM239 cells only. The clonogenic survival assay proved 
the efficacy of this drug in vitro particularly against these 
vertical growth phase melanoma cells. All these findings 
suggest that the classic caspase-dependent apoptotic 
pathway is not involved as a mechanism for Solamar-
gine-induced cellular death in susceptible malignant 
melanoma cells, but rather the extrinsic lysosomal-mito-
chondrial pathway is responsible. Our results indicate 
that Solamargine warrants further attention and addi-
tional in vivo studies will give a clearer idea of the poten-




The glycoalkaloid Solamargine was obtained from Gly-
comix Ltd (Whiteknights Road, UK). The drug was dis-
solved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, 
USA) and prepared as stock solution of 1  mM, stored 
at 4 °C before the experiments and freshly diluted to the 
final concentrations in culture medium without fetal 
bovine serum (FBS).
Cell lines and cell culture
The Human melanoma cell line WM35 was used to 
represent benign radial growth phase (RGP) primary 
melanoma [17, 18]. The two cell lines WM115 and 
WM239 (WM239-A) were used to represent vertical 
growth phase (VGP) primary melanoma and metastatic 
melanoma respectively [19]. Cell lines were authen-
ticated by STR analysis, most recently in March 2015 
(Genetica DNA Laboratories, Burlington, NC, USA). 
Primary bovine aortic endothelial cells (BAEC isolated 
by BLC), rat fibroblast and epithelial cells lines [20] 
were used in this work as control normal cells. All cells 
except WM35 were grown in complete culture medium 
DMEM (Sigma-Aldrich, USA) supplemented with 10  % 
FBS (Sigma-Aldrich, USA), 1  % (v/v) sodium pyruvate 
(Sigma-Aldrich, Germany) and 0.5  % (v/v) gentamycin 
(Gibco, USA). WM35 cells were grown in RPMI media 
(Gibco, USA), supplemented with 10 % (v/v) heat-inacti-
vated fetal bovine serum (FBS) (Hyclone, UK) 1 % (v/v) 
sodium pyruvate and 0.5 % (v/v) gentamycin. Cells were 
grown in a humidified incubator at 37 °C under 5 % CO2.
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alamarBlue proliferation assay
1.5–2.0  ×  104 cells were seeded in 96-well cell culture 
plates in 200 μL complete growth medium per well. Fol-
lowing a 24-hour incubation period, the cells were sepa-
rately treated with serial concentrations of Solamargine 
and ≤0.1  % DMSO (as control) in 100  μl of FBS free 
medium at 37 °C for 12 h. Cellular metabolic activity was 
assessed using alamarBlue assay (TREK Diagnostic Sys-
tem, USA), following the manufacturer’s protocol and the 
procedure we previously described [21, 22].
Cell growth curve analysis with and without Solamargine 
treatment
3  ×  106 cells were seeded in 100-mm culture dishes 
in normal growth medium and incubated at 37  °C in 
5  % CO2. After 24  h, the cells were treated with Sola-
margine IC50 or ≤0.1  % DMSO (as control) in medium 
without FBS for 0, 0.5, 1.0, 1.5, 2.0 and 2.5 h. Cells were 
harvested by trypsinization, stained with trypan blue 
(Sigma-Aldrich, USA) and live cells were enumerated 
by standard laboratory method using a hemocytometer. 
Cell counts were expressed as mean ± standard deviation 
(SD) of two replicates.
Mitochondrial membrane potential assay
The JC-1 (tetraethylbenzimidazolylcarbocyanine iodide) 
mitochondrial membrane potential Assay Kit (abcam, 
USA) was used to determine the percentage of apop-
totic cells (reflected by loss of mitochondrial membrane 
potential) as a result of solamargine treatment. Fifteen 
thousand cells of each of cell line were seeded in a 96 well 
transparent-bottom black plates, allowed to attach over-
night and stained with 20 µM JC-1 in 1X dilution buffer 
for 10  min at 37  °C. Solamargine or the corresponding 
quantity of DMSO was added to the wells for 2  h, and 
the plate was read in a fluorescence plate reader (Synergy 
HTX, Biotek, USA) at Ex475 ± 20 nm/Em530 ± 15 nm. 
The JC-1 ratio of aggregate/monomer, expressed as 
percentage of Control was calculated according to the 
kit instruction manual. This experiment was repeated 
independently three times and the mean percentage 
value ± standard deviation were used.
Clonogenic survival assay
Three million cells were treated with IC50 or IC70 of Sola-
margine or ≤0.1 % DMSO (as control) in medium with-
out FBS for 2  h. Following 2  h of incubation, floating 
cells (conditioned media) were collected, and adherent 
cells were trypsinized. Conditioned medium and trypsin 
suspensions were combined and centrifuged for 5  min 
at 1520×g, then re-suspended in fresh growth medium 
(DMEM with 10  % FBS) and plated in 6 well plates at 
104 cells per well. The same steps were performed with 
control cells. These cells then were incubated for 2 weeks 
at 37  °C in 5 % CO2 chamber, the formed colonies were 
washed with PBS, stained with crystal violet solution 
(25  % methanol and 0.5  % crystal violet) and counted 
manually. This experiment was repeated 3 times by only 
growing the 104 cells as the best dilution at which the col-
onies were countable.
Cell morphology and microscopy
The cells were treated with or without IC50 and IC70 con-
centrations of Solamargine or ≤0.1 % DMSO (as control) 
in medium without FBS. The morphological changes 
were observed after 2 and 24 h and photographed using 
inverted phase contrast microscopy (Zeiss, Germany).
Annexin V measurement of apoptosis
The annexin V-FITC Apoptosis Detection Kit (BioVision, 
USA) was used to detect and quantify apoptosis by flow 
cytometry according to the manufacturer’s instructions. 
In brief, 3 × 106 cells were seeded in 100-mm dishes in 
normal growth medium. The next day, cells were treated 
with IC50 and IC70 of Solamargine, or ≤0.1 % DMSO (as 
control) in medium without FBS for 2  h. Then the cells 
which floated in the conditioned media were washed 
with PBS and collected by centrifugation for 5 min. Cells 
were then re-suspended at a density of 1–5 ×  105 cells 
in 500  µl of binding buffer and stained simultaneously 
with FITC-labeled annexin V (5 µl) and propidium iodide 
(PI) (5 µl). Cells were incubated at room temperature for 
15  min in the dark. Annexin V-FITC binding was ana-
lyzed by flow cytometry (FACS Aria III, BD Biosciences, 
USA) using FITC signal detector and propidium iodide 
(PI) staining by the phycoerythrin emission signal detec-
tor. The data were analyzed using BD FACSDiva™ soft-
ware. A minimum of 10,000 events were acquired per 
sample.
Transmission electron microscopy analysis
For electron microscopic observation, 3 × 106 cells were 
seeded in normal growth medium. The next day, cells 
were treated with IC70 of Solamargine or ≤0.1 % DMSO 
(as control) in medium without FBS for 2 h. Floating cells 
in the conditioned media were centrifuged for 5  min at 
1520×g washed with 1 ml PBS and collected by centrifu-
gation for 5 min. 1 × 106 cells were washed by 200 µl of 
PBS and centrifuged for 3.5 min at 200×g, fixed in 2.5 % 
glutaraldehyde prepared in 0.1  M sodium cacodylate 
buffer—pH 7.2–7.4 for 1  h on ice. Cells were rinsed 
twice with isotonic buffer (0.1  M sodium cacodylate 
buffer—pH 7.2–7.4) each for 5 min on ice. Samples were 
then post-fixed in 1 % OsO4, dehydrated and embedded 
in pure EPOXY resin kit (Agar scientific, UK), labeled, 
and polymerized at 60  °C overnight. Ultra-thin sections 
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(70  nm) were produced and stained with uranyl acetate 
and lead citrate super saturated in 50  % ethanol. Two 
Sections from each treatment were then examined using 
JEOL1230 transmission electron microscope (JEOL, 
USA).
Fluorescent nuclear staining
The cells (15,000) were grown on slides in 10  cm well 
plates, fixed with 4  % paraformaldehyde for 15  min, 
washed 3 times for 5 min each with PBS and stained with 
10 μg/mL propidium iodide (PI) in PBS for 5 min. Slides 
were then washed in PBS, mounted with fluorescent 
mounting media (Dako) and observed under fluorescent 
microscope using the Ex530 nm/Em615 nm filters for PI 
staining.
PAGE and western blot
3 × 106 cells were treated with either IC50 or IC70 of Sola-
margine or ≤0.1 % DMSO (as control) in medium with-
out FBS for 2 h. The whole cell lysates were prepared by 
using ice-cold cell lysis buffer (Cell Signaling Technology, 
USA) mixed with 1  % (v/v) protease inhibitor phenyl-
methylsulfonylfluoride (PMSF) (Millipore, USA) and 1 % 
(v/v) protease inhibitor cocktail (Sigma-Aldrich, USA). 
The cell lysates (100 μg total protein) were loaded in 10 % 
SDS-PAGE and electrophoretically transferred to Immu-
nobilon-PSQPVDF membrane (EMD Millipore, USA). 
The membranes were blocked for 30 min in 5 % nonfat 
milk then incubated overnight at 4 °C with the respective 
primary antibodies (Additional file  1: Table S1) (diluted 
1:1000 in the same blocking solution). Membranes were 
then washed and incubated for 30 min with the appropri-
ate secondary antibody at dilution of 1:20,000 conjugated 
with horseradish peroxidase (Cell Signaling Technology, 
USA). The blots were incubated with enhanced chemilu-
minescence (ECL) solution (mouse/rabbit) (Roche, Ger-
many) and protein bands visualized by subjecting them 
to a sensitive X-ray film (Roche, Germany).
Statistical analysis
All results are presented as mean ±  standard deviation 
(SD). Statistical analysis was performed on the means 
of the triplicate of at least three independent repeated 
experiments using one-way ANOVA test for parametric 
data and Kruskal–Wallis for non-parametric data. Differ-
ences were considered significant when the P values were 
less than 0.05.
Results
Solamargine had a selective inhibition effect on melanoma 
cell proliferation
The drug concentrations that induced 50  % (IC50) and 
70 % (IC70) of melanoma cell death were calculated after 
performing alamarBlue proliferation assay (in four inde-
pendent experiments) as shown in Fig. 1a. IC50 and IC70 
were found to be 6 and 8 µM for VGP primary melanoma 
WM115 and metastatic melanoma WM239 respectively. 
Increasing the drug concentration from 8 to 10  µM did 
not change the percentage of reduced alamarBlue in 
WM239 cells. However, the RGP primary melanoma cell 
line WM35, fibroblast cells, primary epidermal cells and 
BAEC did not show any significant reduction in their 
proliferation even at 10 µM (Fig. 1a). 20 µM was also used 
to check the proliferation of the WM35 cells and there 
was no effect cell proliferated (data not shown), therefore, 
we used the upper limit of 10 µM to represent the IC70.
Growth curve and time course effect of Solamargine 
on melanoma cellular death
In order to assess the effective time of Solamargine 
(IC50) cytotoxicity on melanoma cells, cellular death was 
assessed by counting the number of remaining adherent 
cells every 30  min after the administration of the drug 
for a period of 2.5  h. Solamargine IC50 induced loss of 
WM115 and WM239 cells within the first 2  h of treat-
ment; however Solamargine did not result in any detect-
able cellular death (drop in cellular count) of WM35 
cells within the study period and even after 24 h of drug 
administration (Fig. 1b).
Solamargine profoundly reduced the mitochondrial 
membrane potential in the metastatic cell line WM239
Quantification of changes in mitochondrial membrane 
potential showed that the metastatic VGP melanoma cells 
WM239 were the most affected by Solamargine treat-
ment (Fig.  1c). The JC-1 aggregate signal was reduced 
significantly (P = 0.0019) by 40 % when compared to the 
control cells or to primary lesion WM115 cells, which 
showed a reduction by 14.6  % compared to control 
(P ≥ 0.001). Normal BAEC and the benign WM35 cells 
did not show any significant reduction in mitochondrial 
membrane potential with Solamargine treatment (Fig. 1c; 
P > 0.05).
Solamargine treatment resulted in a differential reduction 
in the ability of melanoma cells to form colonies
Clonogenic survival assay was performed to assess the 
ability of the treated cancer cells to re-grow and re-
form colonies after Solamargine treatment (Fig.  1d, e). 
The number of colonies produced by WM239 cells after 
treatment with the IC50 of Solamargine was significantly 
reduced. The control (DMSO) treated cells WM35, 
WM115, and WM239 cells produced an average of 
71.3 ± 2.9, 85.0 ± 4.6, and 97.3 ± 1.0 colonies/104 cells, 
respectively. However after IC50 Solamargine treatment 
for 2 h, there was significant reduction in the number of 
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colonies subsequently formed by the three cell lines with 
a maximum effect on the metastatic cell line WM239 
which formed an average of only 8.7 ±  1.4 colonies/104 
cells (P < 0.05) (Fig. 1d). Consistent with the results of the 
short-term toxicity assays, RGP WM35 cells displayed 
minor reductions in clonogenic survival upon Solamar-
gine treatment.
Similarly, the number of colonies produced by the 
WM115 and WM239 cells was significantly reduced 
after treatment with the IC70 of Solamargine for 2  h 
(Fig. 1e). The control (DMSO) group of WM35, WM115, 
and WM239 cells produced an average of 71.3  ±  2.9, 
93.0  ±  0.5, and 107.3  ±  3.7 colonies/104 cells, respec-
tively, while the treated groups exhibited 63.0  ±  2.9 
(P < 0.05), 16.0 ± 0.8 (P < 0.05), and 3.0 ± 0.5 (P < 0.05) 
colonies/104 cells, respectively (Fig. 1e).
Cellular morphology changes upon Solamargine treatment
The cells were monitored microscopically after the 
first 2  h of the drug administration and followed up to 
24  h along with control treatment (DMSO). As shown 
in Fig.  2, WM115 and WM239 cells initially became 
rounded in shape and smaller in size, and subsequently 
lost contact with neighboring cells and floated in the 
medium. The morphology of WM35 cells was not 
changed even after 24 h of 10 µM of Solamargine as com-
pared to its respective control (Fig. 2).
Flow cytometry analysis of cellular death events
Since the decrease in cellular proliferation may be a result 
of the induction of apoptosis or necrosis, we quantified 
the number of apoptotic versus necrotic cells in both 
Solamargine treated and control cells at different time 
Fig. 1 Dosage and time effect of Solamargine on cellular proliferation and viability. a Proliferation of WM115 and WM239 as measured by alamar-
Blue assay was reduced by 50 % upon treatment with 6 µM (IC50) of Solamargine, while benign WM35 and the normal cells did not show significant 
reduction in proliferation at doses as high as 10 µM. The graph represents the mean ± S.D (error bars) of four independently repeated experiments. 
b Viability of WM115 and WM239 was reduced by 50 % after 30 min of Solamargine IC50 administration; however WM35 cell viability was not signifi-
cantly affected even after 2.5 h of drug administration. c Mitochondrial membrane potential as revealed by JC-1 aggregate signal was significantly 
reduced in WM239 cells and to a lesser extent in WM115 cells, when compared to control untreated cells. There was no significant reduction in 
mitochondrial membrane potential in either WM35 benign melanoma cells or normal BAEC cells. d and e The IC50 (6 µM) and IC70 (10 µM) of 
Solamargine treatment significantly reduced colony formation ability of all the melanoma cell lines in the study; the most profound decrease was 
noticed in WM239, N = 4, p < 0.0001
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points. As shown in Fig. 3, treatment of melanoma cells 
with Solamargine (10  µM) rapidly induced late apopto-
sis and necrosis as demonstrated by the rapid increase 
in the percentage of the apoptotic (annexin V-positive) 
and necrotic (PI-positive) cells. Most of the PI-stained 
necrotic cells were detected within the first 2 h of Sola-
margine treatment. The necrotic effect of Solamar-
gine was less on the WM35 and BAEC cell lines. After 
treatment with 10 µM Solamargine there was a 1.2 fold 
increase in the PI-stained (necrotic) WM35 cells com-
pared to control cells and 2.8 fold increase in necrotic 
BAEC cells, whereas, 16- and 12-fold increases in the PI-
stained necrotic cells were seen in WM115 and WM239 
cells, respectively. The fold increase of necrosis was cal-
culated as the mean value of four repeated independent 
flow cytometer experiments; Fig. 3 shows representative 
data from one of the four flow cytometer runs. The same 
results were obtained upon exposure to IC50 Solamar-
gine treatment (data not shown). These experiments were 
repeated in four independent runs.
Transmission electron microscopy analysis revealed 
that Solamargine caused necrosis in the vertical growth 
melanoma cell lines selectively
The sub cellular changes associated with Solamar-
gine-induced cell death in melanoma cell lines WM35, 
WM115, and WM239 and BAEC cells were detected 
using Transmission Electron Microscopy. The control 
treatments (DMSO) of the four cell lines BAEC, WM35, 
WM115, WM239 (Fig. 4 a–d top panel) showed no mor-
phological signs of apoptosis or necrosis, displaying 
intact cells with uniform rounded shape, very few vesicles 
(or vacuoles) in the cytoplasm and normal cell organelles. 
Treatment of these cells with 10 µM Solamargine for 2 h 
caused morphological signs of necrosis only in WM115 
and WM239 cells, characterized as evidence of cell lysis 
such as disruptions in plasma membrane, swollen mito-
chondria (Fig. 4f ), increased vacuoles/lysosomes (Fig. 4c 
bottom photo). Some cells showed cytoplasmic vacuola-
tion, increased cell volume, culminating in the disruption 
of the plasma membrane and cell rupture (green arrow) 
Fig. 2 Light microscope images shows that 10 µM Solamargine deformed the malignant but not benign cells. a 2 and b 24 h Solamargine induced 
morphological changes such as cellular rounding up, shrinkage and detachment in malignant WM115 and WM239 cells, but no such changes were 
observed in benign WM35 melanoma cells. Scale bar 50 µm
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leading to the leakage of cellular contents in some cells 
which are morphologic hallmarks of necrosis [23]. The 
nuclear membrane was intact in all the treated cells, and 
staining of treated cultured cells with propidium iodide 
revealed homogeneous nucleic acid distribution with no 
evidence of nuclear condensation or apoptotic body for-
mation (Fig. 4g, h).
Solamargine treatment caused upregulation of tumor 
necrosis factor receptor‑1, cytochrome C and cathepsin B 
and other cell death related proteins in melanoma cells
As shown in Figs.  5a and 6, the expression of TNFR-1 
was extensively up-regulated in WM115 and WM239 
cells treated with 10 μM Solamargine for 2 h compared 
to control, whereas it was only slightly increased in 
Fig. 3 Flow cytometry analysis showed, Solamargine increased apoptosis tenfold more in malignant to benign cells. 10 µM Solamargine treatment 
for 2 h selectively caused massive cellular death of WM115 primary and WM239 metastatic melanoma cells which was at least tenfold more than 
the detected in benign WM35 and/or in BAEC cells.The results shown are for one representative experiment of triplicate determinations
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WM35 cells. Treatment with IC50 Solamargine caused 
the same effect (data not shown). Solamargine (10  µM) 
also significantly increased the levels of cathepsin B 
and cytochrome c in WM115 and WM239 cells but not 
in WM35 cells (Figs.  5a, 6). There was an appreciable 
increase in the proteolytic activity of caspase-3 resulting 
in its cleavage in WM239 cells, which was greater than 
that found in WM115 cells. However this activation of 
caspase-3 was not detected in WM35 cells. FADD levels 
were not affected significantly by Solamargine treatment 
in any melanoma cell line (Fig. 5b).
The anti-apoptotic protein Bcl-2 was up-regulated 
upon treatment in both WM115 and WM239 and 
to a less extent in WM35 cells. Furthermore, 10  µM 
of Solamargine up-regulated the expression of the 
anti-apoptotic protein Bcl-xL in WM115 and WM35 
cells, while no obvious change was observed in WM239 
cells (Figs.  5c, 6). The anti-apoptotic protein XIAP was 
down regulated in WM115 and WM239 cells and was 
slightly increased in WM35 cells treated with 10  µM 
Solamargine (Figs. 5c, 6).
The pro-apoptotic proteins Bax, Apaf-1, Nip-1 and 
Bad were also evaluated by western blot (Fig. 5d). Sola-
margine (10 µM) treatment for 2 h reduced the expres-
sion of Bax and Apaf-1 in WM115 and WM239 cells, 
whereas the expression of these proteins was not affected 
in WM35 cells. The expression of Bad and Nip-1 was not 
affected by 10 µM Solamargine treatment in all three cell 
lines (Fig. 5d).
Fig. 4 TEM images for BAEC, WM35, WM115 and WM239, shows the effect of Solamargine on cellular ultrastructure and fluorescent images shows 
intact nuclei after Solamargine treatment in WM35 and WM239 cells. Top images show control and the bottom panels show 10 µM Solamargine 
treatment for 2 h. Solamargine induced signs of necrosis in WM115 primary melanoma (c) and WM239 metastatic melanoma (d) cells, but benign 
melanoma WM35 (b) and BAEC (a) cells showed milder cell disruption, scale bars 5 µm. e and f Two higher magnification images show the swollen 
mitochondria in WM239 cells compared to the normal looking mitochondria of WM35 cells after their exposure to 10 µm of Solamargine for 2 h. 
Scale bars 0.5 µm. g and h Staining of cultured WM35 and WM239 cells with propidium iodide after 2 h Solamargine treatment shows intact nuclei 
and no signs of nuclear fragmentation or condensation. Scale bars 50 µm
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Discussion
Drug discovery and the search for potent and selective 
anti-cancer agents are valid aims for many scientists 
worldwide. Early in 1987 Cham et al. showed that extracts 
from Solanum plant species possessed antitumor proper-
ties against sarcoma 180 in mice [24]. Later in 2007 they 
reported the effectiveness of a cream containing Solaso-
dine Rhamnosyl Glycosides (SRGs) in the treatment of 
large number of non-melanoma skin cancers in humans 
and horses [11]. In this study we measured the half inhib-
itory concentrations (IC50) of Solamargine on three mela-
noma cell lines representing benign and malignant forms 
of the disease. Our results clearly show that Solamargine 
selectively inhibits the highly proliferating/malignant 
melanoma cells with minimum necrotic effect on benign 
melanoma and normal cells. This result is supported by 
many previous studies done on different types of cancer 
cells. For instance, Solamargine caused cellular death for 
breast cancer cells HBL-100, SK-BR-3 and ZR-75-1 after 
3 h of their exposure to IC50 concentrations of 2.07, 3.00 
and 2.15  µM respectively [9]. However, Solamargine at 
higher concentration (IC50, 8.5  µM) was needed to kill 
human K562 leukaemia cells within 2 h [16]. Human lung 
cancer cells H441, H520, H661 and H69 displayed posi-
tive annexin V staining after 2  h of various concentra-
tions of Solamargine (3–5.8  µM) [25]. All these studies 
together with the current study indicate that Solamargine 
has an anti-proliferative effect against cancer cells and the 
Fig. 5 Representative western blots for the cellular death proteins in the presence and absence of Solamargine. a TNFR1, cytochrome c, and 
cathepsin B were up-regulated in malignant WM115 and WM239 cells while these proteins were not significantly altered in the benign WM35 cells. 
b There were no significant changes for FADD protein however, a slight increase in the cleaved caspase-3 protein was observed in both WM115 
and WM239 cells, respectively. c The anti-apoptotic protein Bcl-2 was up-regulated more profoundly in WM115 and WM239 cells when compared 
to WM35 cells. Solamargine also increased the expression of Bcl-xL in both WM35 and WM115 cells, with no effect on WM239 cells. The expression 
of hILP/XIAP was down regulated in the presence of Solamargine only in WM115 and WM239 cells. d The pro-apoptotic proteins Bax and Apaf-1 
were also down regulated upon the administration of Solamargine in WM115 and WM239, but not WM35 cells. Nip-1 and Bad levels did not change 
significantly with treatment in any cell lines
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growth inhibitory concentration is highly dependent on 
the type of cancer cell. To our knowledge this is the first 
study showing the parallel effect of Solamargine on both 
normal cells as well as the melanoma cells from early and 
advanced lesions (RGP and VGP). We found that the col-
ony formation ability of both WM115 and WM239 cells 
pre-treated with Solamargine was extensively reduced 
while the benign WM35 cells retained their ability to 
form a similar number of colonies to control even after 
their exposure to IC70 of the drug. This clonogenic sur-
vival test was not performed in the previous studies, 
although it is considered the gold standard in vitro assay 
to detect the efficacy of chemotherapy drugs [26].
Flow cytometry analysis indicated that Solamargine 
caused cellular necrosis in the highly proliferating mela-
noma cells (WM115 and WM239) upon the treatment 
with Solamargine at concentrations that did not exert 
effects on either WM35 cells or BAEC. These results 
were consistent with caspase-3 analysis that showed rel-
atively low cleavage in both WM115 and WM239 cells. 
The prominence of the necrosis pathway is further sup-
ported by the changes in mitochondrial function. We 
found at most a 40 % reduction in mitochondrial mem-
brane potential (in WM239 cells) indicating that apop-
tosis is not the primary cause of the rapid cellular death 
observed in the first two hours of treatment. Similar flow 
cytometry results were obtained in different human lung 
cancer cells (H441, H520, H661, H69) treated with Sola-
margine which rapidly (in the first hour of incubation) 
induced apoptosis and increased percentage of annexin 
V-positive cells but only few double-positive necrotic 
cells were detected [25].
Solamargine triggered TNFR1 upregulation in the 
highly proliferative melanoma cells (WM115 and 
WM239) but TNFR1 was only slightly up regulated in the 
slow proliferating WM35 cells. This suggests that TNFR1 
may mediate Solamargine induced necrosis in those cells, 
which sensitizes them to lysosomal cathepsin B medi-
ated by the release of mitochondrial cytochrome c. Such 
effect of cathepsin B was reported in TNFα mediated 
hepatocyte apoptosis [27]. Consistent with our finding, 
Sun et al. [16] reported that 7.5 µM of Solamargine could 
induce early lysosomal rupture in human K562 leuke-
mia cells within 2 h which was confirmed by the release 
Fig. 6 Western blot densitometry and relative intensity of protein bands calculated using image J software. Treatment with Solamargine (10 µM) 
for 2 h resulted in a significant increase in TNFR1 expression in both WM115 and WM239 cells the when compared with control (DMSO) treated cells 
(p = 0.045 and p = 0.012 respectively). Cytochrome c was upregulated significantly after the treatment in both WM115 and WM239 (p = 0.048 and 
p = 0.0329 respectively). Cathepsin B had the same pattern as the former proteins and was upregulated upon Solamargine treatment (p = 0.023 
and p = 0.041 respectively. BCL2 protein was also upregulated significantly upon the treatment in both WM115 and WM239 (p = 0.0001 and 
p = 0.0017 respectively). Unlike the former proteins Bcl-xL was upregulated significantly in the benign WM35 cells and the primary cells VGP WM115 
cells (p = 0.043 and p = 0.021 respectively). hILP/XIAP was down regulated significantly with the treatment in both malignant cell lines WM115 and 
WM239 (p = 0.033 and p = 0.048 respectively), N = 3
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of cathepsin B to cytosol. Previous studies also reported 
that Solamargine at different concentrations increases 
the expression of TNFR-1 in various cancer cells, such as 
lung [25], hepatoma [28], breast [10], and human squa-
mous cell carcinoma [15].
In addition to rapid induction of cell necrosis, we 
obtained evidence that the intrinsic apoptosis pathway 
was also affected and altered in WM115 and WM239 
cells, perhaps due to unbalance between the pro- and 
anti-apoptotic proteins. The anti-apoptotic protein 
XIAP was down regulated in both WM115 and WM239 
cells treated with Solamargine, however it was slightly 
upregulated in WM35 cells. When XIAP is bound to cas-
pase-3, the protease is inhibited, thus if the cell receives 
a signal to undergo apoptosis, Smac/Diablo proteins 
released from the mitochondria bind to XIAP freeing 
up caspase-3 for activation and subsequent apoptosis 
[29]. The above phenomenon may explain our results 
that both WM115 and WM239 cells loose XIAP expres-
sion and display active (cleaved) caspase 3 when treated 
with Solamargine. However benign radial growth phase 
WM35 cells express high levels of XIAP even when 
exposed to Solamargine, and caspase-3 was not cleaved. 
These results were confirmed by the TEM images which 
showed clearly that only the WM115 and WM239 cells 
had evidence of loss of plasma membrane integrity 
and cell rupture. The nuclei in the treated WM115 and 
WM239 cells looked normal which indicates that these 
morphological changes are due to necrotic and not 
apoptotic effects of the drug, since necrotic cells do not 
fragment into discrete corpses as their apoptotic coun-
terparts do. Moreover, their nuclei remain intact and can 
aggregate and accumulate in necrotic tissues [30].
Solamargine treatment up-regulated Bcl2 expression in 
these cells, suggestive of a protective effect. It was pre-
viously reported that Bcl2 inhibition sensitized resistant 
melanoma cells to Apo2/TRAILl (TNF related apoptosis-
inducing ligand) [31]. The related prosurvival protein 
Bcl-xL was highly expressed in control radial growth 
phase WM35 cells and levels slightly increased upon 
treatment. Bcl-xL profoundly increased in WM115 upon 
Solamargine exposure however, its level was not changed 
in WM239 cells. Previous reports showed that the 
expression of Bcl-xL protein is responsible for melanoma 
cell chemoresistance, and inhibiting this anti-apoptotic 
protein increased the chemosensitivity of the cells [7]. 
Therefore the increase in these two anti-apoptotic pro-
teins seen in our studied cells might be as a controversial 
response to counter the action of the drug.
Conclusions
Taken together our results suggest that the mitochondrial 
pathway is involved in Solamargine-induced cell death in 
human malignant melanoma cells [32]. The disruption 
of the mitochondrial membrane in Solamargine treated 
cells was confirmed by electron microscopy. However 
the classic mitochondrial apoptosis pathway (intrinsic 
pathway) is apparently not involved in the Solamargine-
induced cell death both decreases in pro-apoptotic pro-
tein expression and increases in anti-apoptotic protein 
expression in the studied cells.
Cancer cells are growing and dividing much faster than 
normal cells, thus molecules which can potently act to 
quickly stop their proliferation is of high demand for any 
oncology therapeutic setting. Solamargine shows potential 
features as a promising future drug since it acted selec-
tively to rapidly cause necrosis to the highly proliferating 
VGP melanoma cells, but had minimum necrotic effect on 
the benign RGP melanoma and normal cells. Since most 
melanomas show clinical resistance to anti-apoptotic 
drugs [5], Solamargine holds promise as a necrotic inducer 
for the more serious malignant stage melanoma.
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